An analyst at Roth Capital, Joseph Pantginis, earlier noted Ligand LGND may see EPS growth of up to $0.35 over the next few years, as a result of “meaningful” royalty income from Promacta(R).
The product is used to treat persons with severe aplastic anemia (SAA).
Pantginis maintains a $69 PT and Buy rating on LGND.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in